ABSTRACT BACKGROUND Worsening renal function (WRF) associated with renin-angiotensin-aldosterone system (RAAS)
Recent studies suggest that the cause of renal function decline, the circumstances under which it occurs, and the concomitant therapy used may be far more important than the actual occurrence of WRF itself (2) (3) (4) .
Notably, WRF after initiation of renin-angiotensinaldosterone system (RAAS) inhibitors in clinical trials
has not been associated with poor outcome, but WRF is prognostic when it occurs in the placebo group (5) (6) (7) (8) . Furthermore, the benefit associated with RAAS blockade was observed in both patients with and without WRF, implying that WRF does not alter the benefit of therapy.
In the present study, we investigated change in estimated glomerular filtration rate (eGFR) over time, the occurrence of WRF and its association with clinical outcomes, and interaction with randomized treatment in patients with HFpEF included in the I-PRESERVE (Irbesartan in Heart Failure With Preserved Ejection Fraction) trial.
PATIENTS AND METHODS
The design and results of I-PRESERVE have been published previously (9) . In brief, 4,128 patients $60 years of age, with signs and symptoms of HF and a preserved left ventricular ejection fraction ($45%) were randomized to receive placebo or irbesartan 300 mg once daily. Patients were started on 75 mg of irbesartan or placebo once daily. The dose was doubled to 150 mg after 1 to 2 weeks and doubled again to 300 mg after an additional 1 to 2 weeks, as tolerated. Patients with a baseline serum creatinine (SCr) level >221 mmol/l (2.5 mg/dl) were excluded from the study. Patients with an SCr measurement at baseline and at the visit 8 weeks after randomization were included in the present analysis.
GFR AND WRF. The eGFR was calculated by using the simplified Modification of Diet in Renal Disease formula at baseline and subsequent visits ( Damman et al. 
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RESULTS
A total of 3,595 patients (87% of all randomized patients) with an SCr measurement available at both baseline and 8 weeks formed the study population.
Baseline characteristics are shown in Table 1 .
Compared with the entire I-PRESERVE study population, these patients had a slightly higher mean baseline SCr level but a similar eGFR, were more frequently male, and more often had ischemic heart disease, diabetes, and atrial fibrillation (data not shown). WRF at 8 weeks developed in 229 (6.4%) patients.
Patients randomized to irbesartan treatment experienced WRF more often (8.4% vs. 4.3%; odds ratio: 2.07; 95% confidence interval: 1.56 to 2.75; p < 0.001).
The incidence of WRF according to the other prespecified definitions is presented in Online Table 1. WRF at 2 weeks was less frequent compared with the occurrence at 8 weeks. Clinical characteristics of patients with WRF according to treatment allocation are presented in Table 1 . In general, there were few differences between patients with and without WRF; the main differences were presence of diabetes, higher NT-proBNP concentrations, use of diuretics, and treatment with a mineralocorticoid receptor antagonist (MRA). These differences were more pronounced in patients allocated to irbesartan treatment, although the only significant interaction between WRF and treatment allocation was seen for baseline Table 3, Online Table 2 ). In addition, WRF was strongly associated with all secondary outcomes, with a similar magnitude of association ( Table 4, Online Table 3 ). After multivariable adjustment, the interaction between treatment allocation and WRF on the effect of cardiovascular death or HF hospitalization was no longer significant, although it remained so for all-cause mortality, Damman et al. 
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DISCUSSION
In the present study, we found that WRF occurred more frequently in patients allocated to treatment with irbesartan compared with placebo. Overall, the occurrence of WRF was associated with worse clinical outcomes compared with no WRF. This association seemed to be stronger in patients receiving irbesartan compared with placebo, contrasting strikingly with studies of RAAS inhibition in HFrEF (7, 8, 13) . The present study differs from earlier observations because we investigated a chronic HFpEF population, which, to our knowledge, has not been studied before. One study did, however, investigate WRF developing in HFpEF patients admitted for HF. In that study, Rusinaru et al. (15) found that in-hospital WRF was predictive of 7-year outcome but only in patients with a reduced eGFR at baseline.
To date, no substudy is available from the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) study, but an earlier study found no interaction between baseline renal function and type of HF (HFpEF vs. HFrEF) (16) . In the present study, we found that in patients with clinically stable HFpEF, WRF at 8 weeks was independently associated with all cardiovascular outcomes examined and all-cause mortality. Therefore, the overall association between WRF and poor clinical outcomes in chronic HFpEF seems comparable to HFrEF and acute HF. CI ¼ confidence interval; HR ¼ hazard ratio; OR ¼ odds ratio; other abbreviations as in Table 1 .
RAAS INHIBITION, WRF, AND OUTCOME. It has long been known that initiation of a RAAS inhibitor may lead to an increase in SCr (and a decrease in eGFR), which is usually small (17) . This is thought to occur In the context of these previous studies, our findings in patients with HFpEF show some remarkable similarities and differences. First, depending on the definition used, WRF occurred in 6.0% to 14.4% of patients allocated to the irbesartan group, consistent with previous studies in HFrEF in which the incidence was approximately 6% to 10% after starting an angiotensin-converting enzyme inhibitor or Abbreviations as in Tables 1 and 2 . CV ¼ cardiovascular; other abbreviations as in Tables 1 and 2 .
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